(2S)-2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]propanamide


CAS No. : 133865-88-0

(2S)-2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]propanamide,133865-88-0
Product Details
Cat No:M117811
Molecular Formula:C17H19FN2O2
Molecular Weight:302.349
Price:Get quote
We would like to match the lowest price on market if possible.

Your information is safe with us.

refresh
Appearance:Solid powder
Purity: > 98%
Cat No:M117811
Cas No:133865-88-0
Product-Name:(2S)-2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]propanamide
IUPAC Name:(2S)-2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]propanamide
InChI:InChI=1S/C17H19FN2O2/c1-12(17(19)21)20-10-13-6-8-15(9-7-13)22-11-14-4-2-3-5-16(14)18/h2-9,12,20H,10-11H2,1H3,(H2,19,21)/t12-/m0/s1
InChIKey:BHJIBOFHEFDSAU-LBPRGKRZSA-N
SMILES:CC(C(=O)N)NCC1=CC=C(C=C1)OCC2=CC=CC=C2F
Priralfinamide, also known as Ralfinamide, FCE-26742A; NW-1029; PNU-0154339E, is a Na-channel blocker for the treatment of neuropathic pain and other pain conditions such as post-operative dental pain. It has a relatively complex pharmacology, acting as a mixed voltage-gated sodium channel blocker (including Nav1.7), N-type calcium channel blocker, noncompetitive NMDA receptor antagonist, and monoamine oxidase B inhibitor.

1: Di Stefano AF, Radicioni MM, Rusca A. Pressor response to oral tyramine and monoamine oxidase inhibition during treatment with ralfinamide (NW-1029). Neurotox Res. 2013 May;23(4):315-26. doi: 10.1007/s12640-012-9344-5. Epub 2012 Aug 8. PubMed PMID: 22872464.
2: Bauer M, Bliesath H, Leuratti C, Lackner E, Dieterle W, Müller M, Brunner M. Disposition and metabolism of ralfinamide, a novel Na-channel blocker, in healthy male volunteers. Pharmacology. 2010;86(5-6):297-305. doi: 10.1159/000321322. Epub 2010 Nov 11. PubMed PMID: 21071997.
3: Browne LE, Clare JJ, Wray D. Functional and pharmacological properties of human and rat NaV1.8 channels. Neuropharmacology. 2009 Apr;56(5):905-14. doi: 10.1016/j.neuropharm.2009.01.018. Epub 2009 Jan 31. PubMed PMID: 19371587.
4: Zhang SH, Blech-Hermoni Y, Faravelli L, Seltzer Z. Ralfinamide administered orally before hindpaw neurectomy or postoperatively provided long-lasting suppression of spontaneous neuropathic pain-related behavior in the rat. Pain. 2008 Oct 15;139(2):293-305. doi: 10.1016/j.pain.2008.04.020. Epub 2008 Jun 25. PubMed PMID: 18583049.
5: Yamane H, de Groat WC, Sculptoreanu A. Effects of ralfinamide, a Na+ channel blocker, on firing properties of nociceptive dorsal root ganglion neurons of adult rats. Exp Neurol. 2007 Nov;208(1):63-72. Epub 2007 Jul 19. PubMed PMID: 17707373; PubMed Central PMCID: PMC2117901.
6: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 Jul-Aug;27(6):411-61. PubMed PMID: 16179960.
7: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 Mar;27(2):145-59. PubMed PMID: 15834466.
8: Stummann TC, Salvati P, Fariello RG, Faravelli L. The anti-nociceptive agent ralfinamide inhibits tetrodotoxin-resistant and tetrodotoxin-sensitive Na+ currents in dorsal root ganglion neurons. Eur J Pharmacol. 2005 Mar 14;510(3):197-208. PubMed PMID: 15763243.
9: Cattabeni F. Ralfinamide. Newron Pharmaceuticals. IDrugs. 2004 Oct;7(10):935-9. PubMed PMID: 15478019.


Recommended Products
  • CAS No. :75281-25-3
    Product Name:

    4-Hydroxy-13-cis-retinoic Acid

    Cat No: R063836 View details
  • CAS No. :4674-50-4
    Product Name:

    Nootkatone

    Cat No: R063837 View details
  • CAS No. :1700622-06-5
    Product Name:

    N-Des(4-Fluorophenyl)-N-(3-fluorophenyl) Ezetimibe

    Cat No: R063838 View details
  • CAS No. :NA
    Product Name:

    Sitagliptin Maleate Adduct

    Cat No: R063839 View details